TPCN2 and Parkinson disease: With the advance in the knowledge of lysosomal ion channels, multiple of them have been considered as novel targets for neurodegenerative diseases.65,105 For examples, TRPML1 and TPC2 are considered promising druggable targets in neurodegenerative diseases that are partially due to defective autophagy and accumulation of toxic aggregates.129 Accordingly, agonists of TRPML1 and TPC2 may restore autophagy and reduce neurodegeneration in Parkinson, Alzheimer, and other diseases.